Argenx Se (ARGX) EPS (Basic) (2016 - 2026)
Argenx Se (ARGX) posted quarterly EPS (Basic) of $7.59 for Q2 2026, up 88.81% year-on-year from $4.02 in Q2 2025, and up 28.7% on a QoQ basis from $5.9 in Q1 2026.
Argenx Se (ARGX) EPS (Basic) (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported EPS (Basic) for 11 consecutive years, with $7.59 the latest figure, recorded in Q2 2026.
- Quarterly EPS (Basic) rose 88.81% year-over-year to $7.59 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $27.58 (up 31.53% YoY) and the FY2025 annual result came in at $21.08, up 51.46% from the prior year.
- EPS (Basic) advanced to $7.59 in Q2 2026 per ARGX's latest filing, from $5.9 in the prior quarter.
- Over the last five years, EPS (Basic) for ARGX reached as high as $12.93 in Q4 2024 and fell as low as -$4.36 in Q1 2022.
- A 5-year average of $3.11 and a median of $2.15 in 2024 frame the typical range for EPS (Basic).
- The largest YoY upside for EPS (Basic) was 2663.46% in 2022 against a maximum downside of 638.82% in 2022.
- Year by year, EPS (Basic) stood at -$0.71 in 2022, then plunged by 144.31% to -$1.73 in 2023, then surged by 845.59% to $12.93 in 2024, then plunged by 32.77% to $8.69 in 2025, then retreated by 12.7% to $7.59 in 2026.
- According to Business Quant data, EPS (Basic) over the past three periods registered $7.59, $5.9, and $8.69 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 0.00 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.16 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 0.00 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 4.06 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 6.99 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 0.00 |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 7.59 |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -2.29 |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 1.55 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.59 |
| Mar 31, 2026 | 5.90 |
| Dec 31, 2025 | 8.69 |
| Sep 30, 2025 | 5.61 |
| Jun 30, 2025 | 4.02 |
| Mar 31, 2025 | 2.77 |
| Dec 31, 2024 | 12.93 |
| Sep 30, 2024 | 1.52 |
| Jun 30, 2024 | 0.49 |
| Mar 31, 2024 | -1.04 |
| Dec 31, 2023 | -1.73 |
| Sep 30, 2023 | -1.25 |
| Jun 30, 2023 | -1.69 |
| Mar 31, 2023 | 0.52 |
| Dec 31, 2022 | -0.71 |
| Sep 30, 2022 | 4.26 |
| Jun 30, 2022 | 12.41 |
| Mar 31, 2022 | -4.36 |
| Dec 31, 2021 | -4.66 |
| Sep 30, 2021 | -4.54 |